Lagatar24 Desk
New Delhi, Feb 9: Glenmark Pharmaceuticals Limited (Glenmark) and SaNOtize Research & Development Corp., a Canadian pharmaceutical company, today announced the launch of FabiSpray, a Nitric Oxide Nasal Spray for the treatment of adult patients with COVID-19 who are at high risk of disease progression.
As part of the fast approval procedure, Glenmark acquired manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS.
Glenmark launches Nitric Oxide Nasal Spray(FabiSpray®)in India for treatment of adult patients with #COVID19,in partnership with SaNOtize. It received manufacturing-marketing approval from India’s drug regulator for Nitric Oxide Nasal Spray as part of accelerated approval process pic.twitter.com/MVTLu1xZoK
— ANI (@ANI) February 9, 2022
“As a leading pharmaceutical player, it is important that we are an integral part of India’s fight against the COVID-19 pandemic. We are happy to receive regulatory approval for Nitric Oxide Nasal Spray (FabiSpray®) and launch it in partnership with SaNOtize,”Robert Crockart, said Chief Commercial Officer, Glenmark Pharmaceuticals Ltd.
“This reaffirms our commitment to providing yet another safe and effective antiviral treatment for COVID-19, and we are confident it will offer patients a much needed and timely therapy option,” he added.
Notably, FabiSpray Nitric Oxide Nasal Spray, is designed to kill the COVID-19 virus in the upper airways.
